{"id":24919,"date":"2022-10-25T16:27:00","date_gmt":"2022-10-25T08:27:00","guid":{"rendered":"https:\/\/flcube.com\/?p=24919"},"modified":"2025-02-02T16:40:26","modified_gmt":"2025-02-02T08:40:26","slug":"rongsheng-bio-set-for-ipo-on-star-board-to-boost-vaccine-rd","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=24919","title":{"rendered":"Rongsheng Bio Set for IPO on STAR Board to Boost Vaccine R&D"},"content":{"rendered":"\n

Shanghai Rongsheng Biotech Co., Ltd is preparing to conduct an initial public offering (IPO) of 25.5 million shares on the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR). The transaction is expected to raise approximately RMB 1.25 billion (USD 171 million). The funds will be allocated toward the research and development (R&D) of several vaccines, including the Vero cell human rabies vaccine, MRC-5 cell human rabies vaccine, influenza virus split vaccine, and pneumonia vaccine. Additionally, the proceeds will support facilities expansion, R&D of point-of-care testing (POCT) diagnostic reagents, and the varicella-zoster vaccine.<\/p>\n\n\n\n

Company Capabilities and Technology Platforms<\/strong>
Rongsheng Bio boasts a range of capabilities and technology platforms in the vaccine and in vitro diagnostic (IVD) reagents fields. These include cell factory culture technology, large-scale cell culture technology, large-scale virus purification technology, vaccine preparation technology, enzyme-linked immune technology, automated agglutination reaction test technology, and dry fluorescent technology platforms. The company’s IVD reagents segment covers ELISA, agglutination reaction, biochemical diagnosis, colloidal gold method, and more.<\/p>\n\n\n\n

Market Position and Business Strategy<\/strong>
Currently, Rongsheng Bio has only one product on the market: its live attenuated varicella vaccine, which is approved for patients aged 12 months to 12 years. The vaccine generated RMB 215 million (USD 29.4 million) in sales in 2021, accounting for 82.05% of the company’s total revenues. Looking ahead, Rongsheng Bio plans to expand its vaccine and immunodiagnostic reagent businesses while scaling back its biochemical diagnostic reagent business. Revenues from the biochemical diagnostic reagent business have declined from RMB 19.54 million (USD 2.6 million) in 2019 to RMB 6.98 million (USD 955,365) in 2021.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Shanghai Rongsheng Biotech Co., Ltd is preparing to conduct an initial public offering (IPO) of…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[72,3492,12],"class_list":["post-24919","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-ipo","tag-rongsheng-biotech","tag-vaccine"],"yoast_head":"\nRongsheng Bio Set for IPO on STAR Board to Boost Vaccine R&D - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Rongsheng Biotech Co., Ltd is preparing to conduct an initial public offering (IPO) of 25.5 million shares on the Shanghai Stock Exchange's Sci-Tech Innovation Board (STAR). The transaction is expected to raise approximately RMB 1.25 billion (USD 171 million). The funds will be allocated toward the research and development (R&D) of several vaccines, including the Vero cell human rabies vaccine, MRC-5 cell human rabies vaccine, influenza virus split vaccine, and pneumonia vaccine. Additionally, the proceeds will support facilities expansion, R&D of point-of-care testing (POCT) diagnostic reagents, and the varicella-zoster vaccine.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=24919\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rongsheng Bio Set for IPO on STAR Board to Boost Vaccine R&D\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=24919\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-25T08:27:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-02T08:40:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24919#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24919\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Rongsheng Bio Set for IPO on STAR Board to Boost Vaccine R&D\",\"datePublished\":\"2022-10-25T08:27:00+00:00\",\"dateModified\":\"2025-02-02T08:40:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24919\"},\"wordCount\":271,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"IPO\",\"Rongsheng Biotech\",\"Vaccine\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=24919#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24919\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=24919\",\"name\":\"Rongsheng Bio Set for IPO on STAR Board to Boost Vaccine R&D - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-10-25T08:27:00+00:00\",\"dateModified\":\"2025-02-02T08:40:26+00:00\",\"description\":\"Shanghai Rongsheng Biotech Co., Ltd is preparing to conduct an initial public offering (IPO) of 25.5 million shares on the Shanghai Stock Exchange's Sci-Tech Innovation Board (STAR). The transaction is expected to raise approximately RMB 1.25 billion (USD 171 million). The funds will be allocated toward the research and development (R&D) of several vaccines, including the Vero cell human rabies vaccine, MRC-5 cell human rabies vaccine, influenza virus split vaccine, and pneumonia vaccine. Additionally, the proceeds will support facilities expansion, R&D of point-of-care testing (POCT) diagnostic reagents, and the varicella-zoster vaccine.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24919#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=24919\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24919#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rongsheng Bio Set for IPO on STAR Board to Boost Vaccine R&D\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Rongsheng Bio Set for IPO on STAR Board to Boost Vaccine R&D - Insight, China's Pharmaceutical Industry","description":"Shanghai Rongsheng Biotech Co., Ltd is preparing to conduct an initial public offering (IPO) of 25.5 million shares on the Shanghai Stock Exchange's Sci-Tech Innovation Board (STAR). The transaction is expected to raise approximately RMB 1.25 billion (USD 171 million). The funds will be allocated toward the research and development (R&D) of several vaccines, including the Vero cell human rabies vaccine, MRC-5 cell human rabies vaccine, influenza virus split vaccine, and pneumonia vaccine. Additionally, the proceeds will support facilities expansion, R&D of point-of-care testing (POCT) diagnostic reagents, and the varicella-zoster vaccine.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=24919","og_locale":"en_US","og_type":"article","og_title":"Rongsheng Bio Set for IPO on STAR Board to Boost Vaccine R&D","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=24919","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-10-25T08:27:00+00:00","article_modified_time":"2025-02-02T08:40:26+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=24919#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=24919"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Rongsheng Bio Set for IPO on STAR Board to Boost Vaccine R&D","datePublished":"2022-10-25T08:27:00+00:00","dateModified":"2025-02-02T08:40:26+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=24919"},"wordCount":271,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["IPO","Rongsheng Biotech","Vaccine"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=24919#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=24919","url":"https:\/\/flcube.com\/?p=24919","name":"Rongsheng Bio Set for IPO on STAR Board to Boost Vaccine R&D - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-10-25T08:27:00+00:00","dateModified":"2025-02-02T08:40:26+00:00","description":"Shanghai Rongsheng Biotech Co., Ltd is preparing to conduct an initial public offering (IPO) of 25.5 million shares on the Shanghai Stock Exchange's Sci-Tech Innovation Board (STAR). The transaction is expected to raise approximately RMB 1.25 billion (USD 171 million). The funds will be allocated toward the research and development (R&D) of several vaccines, including the Vero cell human rabies vaccine, MRC-5 cell human rabies vaccine, influenza virus split vaccine, and pneumonia vaccine. Additionally, the proceeds will support facilities expansion, R&D of point-of-care testing (POCT) diagnostic reagents, and the varicella-zoster vaccine.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=24919#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=24919"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=24919#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Rongsheng Bio Set for IPO on STAR Board to Boost Vaccine R&D"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24919","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=24919"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24919\/revisions"}],"predecessor-version":[{"id":24922,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24919\/revisions\/24922"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=24919"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=24919"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=24919"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}